Identification of Potential Biomarkers in PDAC Public Deposited

Downloadable Content

Download PDF
Last Modified
  • March 19, 2019
  • Whittlesey, Rebecca
    • Affiliation: School of Medicine, Curriculum in Genetics and Molecular Biology
  • Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in both men and women in the United States, with a 5-year survival rate of approximately 6%. The poor prognosis associated with PDAC emphasizes the need to improve detection and screening, therefore we aimed to identify new biomarkers associated with PDAC progression. 137 cancer associated genes identified from our microarray data were screened for gene expression using 13 PDAC cell lines and 42 samples isolated from the blood of 21 PDAC and 4 control patients. 56 genes were found to have expression in >70% of PDAC cell lines and low expression in control buffy coat samples. 16 of these genes showed significant survival differences in patients with low expression when analyzed in our microarray data. Two of these genes, GJB3 and MFI2, showed a trend of higher expression in metastatic PDAC patients compared to benign or local PDAC patients. GJB3 and MFI2 may have clinical relevance for patient survival and be useful as metastatic biomarkers for PDAC, but improved sample isolation techniques and screening of more samples is needed to determine their significance.
Date of publication
Resource type
Rights statement
  • In Copyright
  • Yeh, Jen Jen
  • Sekelsky, Jeff
  • Kim, William
  • Master of Science
Degree granting institution
  • University of North Carolina at Chapel Hill Graduate School
Graduation year
  • 2014
Place of publication
  • Chapel Hill, NC
  • There are no restrictions to this item.

This work has no parents.